Cowealth Medical China Co.,Ltd. (SHA:603122)
China · Delayed Price · Currency is CNY 15.55
+0.12 (0.78%)
At close: Apr 28, 2026
Cowealth Medical China Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 656.1 | 677.51 | 938.79 | 1,092 | 1,279 | 1,191 |
Other Revenue | 0.28 | 0.28 | 0.35 | 0.33 | 0.33 | 0.32 |
| 656.38 | 677.79 | 939.14 | 1,093 | 1,280 | 1,191 | |
Revenue Growth (YoY) | -25.09% | -27.83% | -14.05% | -14.62% | 7.44% | 9.37% |
Cost of Revenue | 564.13 | 583.02 | 763.98 | 870.46 | 1,024 | 943.35 |
Gross Profit | 92.25 | 94.77 | 175.16 | 222.14 | 255.43 | 247.71 |
Selling, General & Admin | 116.94 | 120.73 | 147.76 | 158.86 | 147.54 | 139.23 |
Research & Development | 4 | 3.81 | 3.75 | 3.18 | 2.8 | - |
Other Operating Expenses | -1.64 | -1.17 | -1.18 | -1.49 | 3.75 | 3.45 |
Operating Expenses | 132 | 136.07 | 140.09 | 157.67 | 156.56 | 145.67 |
Operating Income | -39.75 | -41.3 | 35.07 | 64.48 | 98.87 | 102.03 |
Interest Expense | -2.32 | -2.32 | -3.32 | -5.88 | -4.24 | -4.55 |
Interest & Investment Income | 5.66 | 5.66 | 4.15 | 9.34 | 9.77 | 4.67 |
Currency Exchange Gain (Loss) | -0.91 | -0.91 | 0.92 | -0.03 | 0.78 | -0.22 |
Other Non Operating Income (Expenses) | -4.36 | -0.77 | 0.21 | -3.88 | -0.27 | 0.76 |
EBT Excluding Unusual Items | -41.68 | -39.64 | 37.03 | 64.04 | 104.91 | 102.69 |
Gain (Loss) on Sale of Investments | -0.26 | -0.21 | -1.15 | -1.38 | - | - |
Gain (Loss) on Sale of Assets | 0 | 0.04 | 0.44 | 0.08 | -0.16 | -0 |
Asset Writedown | 0.25 | - | - | - | - | - |
Other Unusual Items | -0.31 | -0.31 | 3.15 | 2.96 | 9.1 | 6.83 |
Pretax Income | -42 | -40.12 | 39.47 | 65.7 | 113.84 | 109.52 |
Income Tax Expense | -6.21 | -6.43 | 11 | 18.54 | 31.13 | 29.35 |
Earnings From Continuing Operations | -35.79 | -33.69 | 28.47 | 47.16 | 82.72 | 80.16 |
Minority Interest in Earnings | -0.14 | 0.04 | -0.9 | 0.03 | 0 | 0.07 |
Net Income | -35.93 | -33.64 | 27.57 | 47.19 | 82.72 | 80.23 |
Net Income to Common | -35.93 | -33.64 | 27.57 | 47.19 | 82.72 | 80.23 |
Net Income Growth | - | - | -41.58% | -42.96% | 3.10% | 10.58% |
Shares Outstanding (Basic) | 449 | 421 | 394 | 393 | 376 | 297 |
Shares Outstanding (Diluted) | 449 | 421 | 394 | 393 | 376 | 297 |
Shares Change (YoY) | 18.29% | 6.79% | 0.15% | 4.58% | 26.53% | -1.71% |
EPS (Basic) | -0.08 | -0.08 | 0.07 | 0.12 | 0.22 | 0.27 |
EPS (Diluted) | -0.08 | -0.08 | 0.07 | 0.12 | 0.22 | 0.27 |
EPS Growth | - | - | -41.67% | -45.45% | -18.52% | 12.50% |
Free Cash Flow | -90.99 | 3.47 | 100.93 | -56.68 | -56.31 | -15.11 |
Free Cash Flow Per Share | -0.20 | 0.01 | 0.26 | -0.14 | -0.15 | -0.05 |
Dividend Per Share | - | - | 0.130 | 0.060 | 0.150 | 0.180 |
Dividend Growth | - | - | 116.67% | -60.00% | -16.67% | - |
Gross Margin | 14.05% | 13.98% | 18.65% | 20.33% | 19.96% | 20.80% |
Operating Margin | -6.06% | -6.09% | 3.73% | 5.90% | 7.73% | 8.57% |
Profit Margin | -5.47% | -4.96% | 2.94% | 4.32% | 6.46% | 6.74% |
Free Cash Flow Margin | -13.86% | 0.51% | 10.75% | -5.19% | -4.40% | -1.27% |
EBITDA | -32.16 | -33.81 | 42.17 | 71.65 | 106.92 | 112.66 |
EBITDA Margin | -4.90% | -4.99% | 4.49% | 6.56% | 8.36% | 9.46% |
D&A For EBITDA | 7.59 | 7.49 | 7.1 | 7.17 | 8.05 | 10.63 |
EBIT | -39.75 | -41.3 | 35.07 | 64.48 | 98.87 | 102.03 |
EBIT Margin | -6.06% | -6.09% | 3.73% | 5.90% | 7.73% | 8.57% |
Effective Tax Rate | - | - | 27.87% | 28.21% | 27.34% | 26.80% |
Revenue as Reported | 677.79 | 677.79 | 939.14 | 1,093 | 1,280 | 1,191 |
Advertising Expenses | - | 2.37 | 4.06 | 3.61 | 4.65 | 2.32 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.